Moberg Pharma AB (publ) (MOB.ST)
Moberg Pharma AB (publ) operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Bromma, AB, SE. The stock last traded at $11.26, down 0.35% on the session, giving a market capitalisation of $531.3M. Its beta of 0.74 implies it has historically moved less than the broad market.
Moberg Pharma AB (publ) functions as a pharmaceutical company, dedicated to both crafting and globally marketing medical solutions throughout Europe, the United States, and various international territories. A notable product within its development portfolio is MOB-015, a treatment designed for nail fungus, which has successfully concluded its Phase III clinical trials. Established in 2006, this enterprise is headquartered in Bromma, Sweden. It was previously known as Moberg Derma AB (publ) until its rebranding to the current name in May 2013.
Moberg Pharma AB (publ) is most often compared with the following Healthcare names: